| A CGRP receptor antagonist being developed by Pfizer, under a license from Bristol-Myers Squibb, for the prevention and treatment of chronic and episodic migraine. |
| Received its first approval on 9 March 2023 in the USA as a nasal spray formulation (ZAVZPRET™). |
| Approved for the acute treatment of migraine with or without aura in adults. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.